Cargando…

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer

Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) can induce durable complete tumor regression in patients with advanced melanoma. Efforts are currently underway to expand this treatment modality to other cancer types. In the microenvironment of ovarian cancer, the en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friese, Christina, Harbst, Katja, Borch, Troels Holz, Westergaard, Marie Christine Wulff, Pedersen, Magnus, Kverneland, Anders, Jönsson, Göran, Donia, Marco, Svane, Inge Marie, Met, Özcan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054305/ https://www.ncbi.nlm.nih.gov/pubmed/32127601 http://dx.doi.org/10.1038/s41598-020-60738-4

Ejemplares similares

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
por: Kverneland, Anders Handrup, et al.
Publicado: (2020)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
por: Draghi, Arianna, et al.
Publicado: (2021)

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2020)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2019)

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2019)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
por: Crowther, Michael D., et al.
Publicado: (2020)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
por: Kverneland, Anders H., et al.
Publicado: (2018)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2017)

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2020)

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
por: Jensen, Christina, et al.
Publicado: (2018)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
por: Lesterhuis, W. Joost, et al.
Publicado: (2013)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
por: Hickman, Amber, et al.
Publicado: (2022)

Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
por: Fjæstad, Klaire Yixin, et al.
Publicado: (2022)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
por: Hansen, Ulla Kring, et al.
Publicado: (2020)

Real-world evidence to guide healthcare policies in oncology
por: Donia, Marco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mapb0lmnjhjb480tdv2u17fiuh